Search

Your search keyword '"Klein, Adam M."' showing total 251 results
Start Over Author "Klein, Adam M."
251 results on '"Klein, Adam M."'

3. A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis.

Author

Best, Simon R., Bock, Jonathan M., Fowler, Nicole B., Raabe, Eric H., Klein, Adam M., Laetsch, Theodore W., McClellan, Kim, Rinkel, Rico N.P.M., Saba, Nabil F., Sidell, Douglas R., Tansey, James B., Tunkel, David E., Young, Geoffrey D., and Zur, Karen B.

Abstract

Objective: To provide detailed guidance on the administration of systemic bevacizumab in patients with recurrent respiratory papillomatosis (RRP) based on a detailed review of the scientific literature and a consensus of experts with real‐world clinical experience. Methods: A bevacizumab consensus working group (N = 10) was composed of adult and pediatric otolaryngologists, adult and pediatric oncologists, and a representative from the RRP Foundation (RRPF), all with experience administering systemic bevacizumab in patients with RRP. After extensive review of the medical literature, a modified Delphi method‐based survey series was utilized to establish consensus on the following key areas: clinical and patient characteristics ideal for treatment candidacy, patient perspective in treatment decisions, treatment access, initial dosing, monitoring, guidelines for tapering and discontinuation, and reintensifying therapy. Results: Seventy‐nine statements were identified across nine critical domains, and 45 reached consensus [clinical benefits of bevacizumab (3), patient and disease characteristics for treatment consideration (7), contraindications for treatment (3), shared decision‐making (incorporating the patient perspective) (5), treatment access (3), initial dosing and administration (8), monitoring (7), tapering and discontinuation (6), and reintensification (3)]. Conclusion: This consensus statement provides the necessary guidance for clinicians to initiate systemic administration of bevacizumab and represents a potential paradigm shift toward nonsurgical treatment options for patients with RRP. Level of Evidence: 5 Laryngoscope, 134:5041–5046, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Blood‐Based Proteomics for Adult‐Onset Focal Dystonias.

Author

Timsina, Jigyasha, Dinasarapu, Ashok, Kilic‐Berkmen, Gamze, Budde, John, Sung, Yun Ju, Klein, Adam M., Cruchaga, Carlos, and Jinnah, H. A.

Subjects
MOVEMENT disorders, FOCAL dystonia, PROTEOMICS, BLOOD proteins, ION transport (Biology), BLOOD plasma
Abstract

Objectives: The adult‐onset focal dystonias are characterized by over‐active muscles leading to abnormal movements. For most cases, the etiology and pathogenesis remain unknown. In the current study, unbiased proteomics methods were used to identify potential changes in blood plasma proteins. Methods: A large‐scale unbiased proteomics screen was used to compare proteins (N = 6,345) in blood plasma of normal healthy controls (N = 49) with adult‐onset focal dystonia (N = 143) consisting of specific subpopulations of cervical dystonia (N = 45), laryngeal dystonia (N = 49), and blepharospasm (N = 49). Pathway analyses were conducted to identify relevant biological pathways. Finally, protein changes were used to build a prediction model for dystonia. Results: After correction for multiple comparisons, 15 proteins were associated with adult‐onset focal dystonia. Subgroup analyses revealed some proteins were shared across the dystonia subgroups while others were unique to 1 subgroup. The top biological pathways involved changes in the immune system, metal ion transport, and reactive oxygen species. A 4‐protein model showed high accuracy in discriminating control individuals from dystonia cases [average area under the curve (AUC) = 0.89]. Interpretation: These studies provide novel insights into the etiopathogenesis of dystonia, as well as novel potential biomarkers. ANN NEUROL 2024;96:110–120 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Demographics and Clinical Characteristics Associated with the Spread of New‐Onset Laryngeal Dystonia.

Author

Ghanouni, Arian, Jona, Nikitha, Jinnah, Hyder A., Kilic‐Berkmen, Gamze, Shelly, Sandeep, and Klein, Adam M.

Abstract

Objectives: Adult‐onset idiopathic laryngeal dystonia (LD) can be associated with the risk of spread to muscles in the body. Subjects with extralaryngeal onset of dystonia have exhibited spread to the larynx. Previous studies analyze the spread of other dystonias but emphasis has not been placed on LD. The objective was to identify demographic and clinical factors contributing to the spread of dystonia to and from the larynx. Methods: Data were obtained from the Dystonia Coalition (DC)‐patients from 49 international clinical centers. Clinical and demographic data was taken from 143 out of 409 patients with diagnosed LD. Patient criteria included adult‐onset LD diagnosed on exam with no co‐morbid neurologic conditions and no dystonia in other locations. Results: Among the 143 patients, 94 (65.7%) patients were diagnosed with focal laryngeal onset, with the remainder having extralaryngeal onset. Family history and age at study were statistically significant indicators of a patient developing laryngeal versus extralaryngeal onset of dystonia. Among the laryngeal onset group, 21 cases (22.3%) had an average time of 5.81 ± 5.79 years to spread from diagnosis, most commonly to neck (61.9%). Among extralaryngeal onset patients, mean time of larynx spread was 7.92 ± 7.737 years, most commonly to neck (22.7%). Conclusions: Our data indicates approximately a quarter of patients with laryngeal‐onset dystonia will exhibit spread. There were no demographic or clinical factors that were statistically predictive of the likelihood of spread from larynx. Patients with dystonia elsewhere in the body should be counseled on the possibility of spread to larynx, and vice versa. Level of Evidence: 4 Laryngoscope, 134:2295–2299, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement

Author

So, Raymond J., primary, Hidalgo Lopez, Julio C., additional, Ballestas, Samir A., additional, Klein, Adam M., additional, Steuer, Conor, additional, Shin, Dong M., additional, Abousaud, Marin, additional, Teng, Yong, additional, Saba, Nabil F., additional, Tkaczuk, Andrew T., additional, Schaefer, Eric S., additional, Seiwert, Tanguy Y., additional, McClellan, Kim, additional, and Best, Simon R., additional

Published
2023
Full Text
View/download PDF

12. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.

Author

So, Raymond J., Hidalgo Lopez, Julio C., Ballestas, Samir A., Klein, Adam M., Steuer, Conor, Shin, Dong M., Abousaud, Marin, Teng, Yong, Saba, Nabil F., Tkaczuk, Andrew T., Schaefer, Eric S., Seiwert, Tanguy Y., McClellan, Kim, and Best, Simon R.

Abstract

Objectives: Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP are limited. This study's objective was to characterize disease response of pulmonary RRP to systemic bevacizumab. Methods: A retrospective review was performed to identify patients with pulmonary RRP seen at three medical institutions. Clinical symptoms, CT findings, and disease response were compared before and after initiation of systemic bevacizumab therapy. Disease response was categorized as complete response, partial response, stabilization, or progression for each subsite involved by papilloma. Results: Of the 12 pulmonary RRP patients treated with systemic bevacizumab, 4 (33.3%) were male, and 11 (91.7%) were juvenile‐onset RRP patients. All presented with laryngeal, tracheal, and pulmonary RRP. The median (range) age at first bevacizumab infusion was 48.1 (19.5–70.2) years. Progression to pulmonary malignancy was identified in 3 (25.0%) patients, 2 before initiation of and 1 after complete cessation of bevacizumab therapy. Clinical symptoms such as dyspnea (75.0% vs. 25.0%; p = 0.01) and dysphagia and/or odynophagia (33.3 vs. 0.0%; p = 0.03) were significantly decreased following bevacizumab therapy. Compared with pre‐treatment baseline, 9 (75.0%) patients experienced a stable‐to‐partial response in the lungs to systemic bevacizumab, and 10 (83.3%) experienced partial‐to‐complete responses in the larynx and trachea. Conclusion: Systemic bevacizumab is effective in stabilizing progression in even the most severe cases of RRP, with both a dramatic reduction in laryngeal and tracheal disease as well as a stable‐to‐partial response of pulmonary involvement in a majority of patients. Level of Evidence: 4 Laryngoscope, 134:577–581, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Interim Results of a Phase 1/2 Open‐Label Study of INO ‐3107 for HPV ‐6 and/or HPV ‐11‐Associated Recurrent Respiratory Papillomatosis

Author

Mau, Ted, primary, Amin, Milan R., additional, Belafsky, Peter C., additional, Best, Simon R., additional, Friedman, Aaron D., additional, Klein, Adam M., additional, Lott, David G., additional, Paniello, Randal C., additional, Pransky, Seth M., additional, Saba, Nabil F., additional, Howard, Tamara, additional, Dallas, Michael, additional, Patel, Aditya, additional, Morrow, Matthew P., additional, and Skolnik, Jeffrey M., additional

Published
2023
Full Text
View/download PDF

14. Supplementary Table from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Author

Shin, Dong M., primary, Nannapaneni, Sreenivas, primary, Patel, Mihir R., primary, Shi, Qiuying, primary, Liu, Yuan, primary, Chen, Zhengjia, primary, Chen, Amy Y., primary, El-Deiry, Mark W., primary, Beitler, Jonathan J., primary, Steuer, Conor E., primary, Roser, Steven M., primary, Klein, Adam M., primary, Owonikoko, Taofeek K., primary, Ramalingam, Suresh S., primary, Khuri, Fadlo R., primary, Chen, Zhuo G., primary, and Saba, Nabil F., primary

Published
2023
Full Text
View/download PDF

15. Sppelementary Figures from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Author

Shin, Dong M., primary, Nannapaneni, Sreenivas, primary, Patel, Mihir R., primary, Shi, Qiuying, primary, Liu, Yuan, primary, Chen, Zhengjia, primary, Chen, Amy Y., primary, El-Deiry, Mark W., primary, Beitler, Jonathan J., primary, Steuer, Conor E., primary, Roser, Steven M., primary, Klein, Adam M., primary, Owonikoko, Taofeek K., primary, Ramalingam, Suresh S., primary, Khuri, Fadlo R., primary, Chen, Zhuo G., primary, and Saba, Nabil F., primary

Published
2023
Full Text
View/download PDF

17. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Author

Wise, Sarah K., primary, Damask, Cecelia, additional, Roland, Lauren T., additional, Ebert, Charles, additional, Levy, Joshua M., additional, Lin, Sandra, additional, Luong, Amber, additional, Rodriguez, Kenneth, additional, Sedaghat, Ahmad R., additional, Toskala, Elina, additional, Villwock, Jennifer, additional, Abdullah, Baharudin, additional, Akdis, Cezmi, additional, Alt, Jeremiah A., additional, Ansotegui, Ignacio J., additional, Azar, Antoine, additional, Baroody, Fuad, additional, Benninger, Michael S., additional, Bernstein, Jonathan, additional, Brook, Christopher, additional, Campbell, Raewyn, additional, Casale, Thomas, additional, Chaaban, Mohamad, additional, Chew, Fook Tim, additional, Chambliss, Jeffrey, additional, Cianferoni, Antonella, additional, Custovic, Adnan, additional, Davis, Elizabeth Mahoney, additional, DelGaudio, John M., additional, Ellis, Anne K., additional, Flanagan, Carrie, additional, Fokkens, Wytske J., additional, Franzese, Christine, additional, Greenhawt, Matthew, additional, Gill, Amarbir, additional, Halderman, Ashleigh, additional, Hohlfeld, Jens M., additional, Incorvaia, Cristoforo, additional, Joe, Stephanie A., additional, Joshi, Shyam, additional, Kuruvilla, Merin Elizabeth, additional, Kim, Jean, additional, Klein, Adam M., additional, Krouse, Helene J., additional, Kuan, Edward C., additional, Lang, David, additional, Larenas‐Linnemann, Desiree, additional, Laury, Adrienne M., additional, Lechner, Matt, additional, Lee, Stella E., additional, Lee, Victoria S., additional, Loftus, Patricia, additional, Marcus, Sonya, additional, Marzouk, Haidy, additional, Mattos, Jose, additional, McCoul, Edward, additional, Melen, Erik, additional, Mims, James W., additional, Mullol, Joaquim, additional, Nayak, Jayakar V., additional, Oppenheimer, John, additional, Orlandi, Richard R., additional, Phillips, Katie, additional, Platt, Michael, additional, Ramanathan, Murugappan, additional, Raymond, Mallory, additional, Rhee, Chae‐Seo, additional, Reitsma, Sietze, additional, Ryan, Matthew, additional, Sastre, Joaquin, additional, Schlosser, Rodney J., additional, Schuman, Theodore A., additional, Shaker, Marcus S., additional, Sheikh, Aziz, additional, Smith, Kristine A., additional, Soyka, Michael B., additional, Takashima, Masayoshi, additional, Tang, Monica, additional, Tantilipikorn, Pongsakorn, additional, Taw, Malcolm B., additional, Tversky, Jody, additional, Tyler, Matthew A., additional, Veling, Maria C., additional, Wallace, Dana, additional, Wang, De Yun, additional, White, Andrew, additional, Zhang, Luo, additional, Ahmed, Omar G., additional, Arianpour, Khashayar, additional, Barrow, Emily, additional, Cavaliere, Carlo, additional, Cantu, Juan Carlos Ceballos, additional, Chaskes, Mark B., additional, Chua, Andy Jian Kai, additional, Daggumati, Srihari, additional, Daines, Luke, additional, Daraei, Paul, additional, Edwards, Thomas, additional, Gigliotti, Deanna, additional, Gore, Mitchell, additional, Goshtasbi, Khodayar, additional, Han, Doo Hee, additional, Hossenbaccus, Lubnaa, additional, Jolicoeur, Megan, additional, Kanjanawasee, Dichapong, additional, Kilic, Suat, additional, Linton, Sophia, additional, Liu, David, additional, Low, Christoper, additional, Mahomva, Chengetai, additional, Malenke, Jordan A., additional, Miglani, Amar, additional, Nagy, Peter, additional, Park, Jin‐A, additional, Paz‐Lansberg, Marianella, additional, Pfeffer, Paul, additional, Ryan, Marisa, additional, Saraswathula, Anirudh, additional, Sheehan, Cameron, additional, Struss, Nadja, additional, Tie, Kevin, additional, Torabi, Sina, additional, Tsai, Esmond F., additional, Velasquez, Nathalia, additional, Vuncannon, Jackson, additional, Watley, Duncan, additional, and Xu, Xinni, additional

Published
2023
Full Text
View/download PDF

23. Thoracic Duct Occlusion Leading to Intermittent Left Supraclavicular Swelling and Pancreatitis.

Author

Jona, Nikitha, Majdalany, Bill S., and Klein, Adam M.

Abstract

Intermittent left supraclavicular swelling is an uncommon and elusive condition that can lead to extensive diagnostic workups to determine the etiology and treatment. One potential cause is partial, intermittent, or complete thoracic duct occlusion (TDO). We report on a patient who presented with chronic, intermittent left supraclavicular swelling and abdominal pain that was relieved by thoracic duct angioplasty. Thoracic duct occlusion should be included in the differential diagnosis of left supraclavicular swelling. Lymphatic imaging can facilitate the diagnosis and allows for potential percutaneous treatment. Laryngoscope, 134:1313–1315, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Phase 1B Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Author

Shin, Dong M., Nannapaneni, Sreenivas, Patel, Mihir, Shi, Quiying, Liu, Yuan, Chen, Zhengjia, Chen, Amy, El-Deiry, Mark W., Beitler, Jonathan J., Steuer, Conor, Roser, Steven, Klein, Adam M., Owonikoko, Taofeek, Ramalingam, Suresh, Khuri, Fadlo R., Chen, Zhuo G., and Saba, Nabil F.

Subjects
Adult, Male, Maximum Tolerated Dose, Tea, Kaplan-Meier Estimate, Middle Aged, Article, Catechin, Progression-Free Survival, Erlotinib Hydrochloride, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Precancerous Conditions, Protein Kinase Inhibitors, Aged
Abstract

PURPOSE: Based on synergistic effects between green tea polyphenon E (PPE) and epidermal growth factor receptor-tyrosine kinase inhibitor in preclinical studies, we conducted a phase 1b study of the PPE and erlotinib combination in patients with advanced premalignant lesions (APL) of the oral cavity and larynx. PATIENTS AND METHODS: Patients were treated with a fixed dose of PPE (200mg 3x day) and dose escalation of erlotinib (50, 75, 100 mg daily) for 6-months (6-M) with tissue biopsy at baseline and 6-M. Primary endpoints were safety and toxicity, secondary endpoints were evaluation of pathologic response, cancer free survival (CFS), overall survival (OS) and biomarker modulation. RESULTS: Among 21 enrolled patients, 19 began treatment and 17 completed 6 months of treatment with PPE and erlotinib. Main characteristics of treated patients: 15 severe dysplasia or carcinoma in situ; 17 oral cavity. Only skin rash was associated with DLT and MTD. Recommended doses for phase 2 studies are PPE 600mg daily plus erlotinib 100mg daily for 6-M. Pathologic responses in 17 evaluable patients: pCR (47%) and pPR (18%). The 5-year CFS and OS were 66.3% and 93%, respectively. Among tested biomarkers, only pERK was correlated with response to treatment. CONCLUSION: Treatment with PPE and erlotinib combination was well tolerated in patients with APLs of the head and neck, and showed a high rate of pathologic response with excellent CFS. This combination deserves further investigation for the chemoprevention and/or prevention of second primary tumors in early stage head and neck cancer.

Published
2020

37. Malignant mimickers: chronic bacterial and fungal infections of the larynx

Author

Klein, Adam M., Tiu, Christopher, and Lafreniere, Denis

Subjects
Laryngeal diseases -- Diagnosis -- Care and treatment, Arts, visual and performing, Health, Diagnosis, Care and treatment
Abstract

Summary: Chronic infections of the larynx are notorious 'copycats' of squamous cell carcinoma. Patients typically present with a historical picture and symptoms identical to those seen in a neoplastic setting: [...]

Published
2005

38. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Author

Sidell, Douglas R., primary, Balakrishnan, Karthik, additional, Best, Simon R., additional, Zur, Karen, additional, Buckingham, Julia, additional, De Alarcon, Alessandro, additional, Baroody, Fuad M., additional, Bock, Jonathan M., additional, Boss, Emily F., additional, Bower, Charles M., additional, Campisi, Paolo, additional, Chen, Sharon F., additional, Clarke, Jeffrey M., additional, Clarke, Kevin D., additional, Cocciaglia, Alejandro, additional, Cotton, Robin T., additional, Cuestas, Giselle, additional, Davis, Kara L., additional, DeFago, Victor H., additional, Dikkers, Frederik G., additional, Dossans, Ines, additional, Florez, Walter, additional, Fox, Elizabeth, additional, Friedman, Aaron D., additional, Grant, Nazaneen, additional, Hamdi, Osama, additional, Hogikyan, Norman D., additional, Johnson, Kaalan, additional, Johnson, Liane B., additional, Johnson, Romaine F., additional, Kelly, Peggy, additional, Klein, Adam M., additional, Lawlor, Claire M., additional, Leboulanger, Nicolas, additional, Levy, Alejandro G., additional, Lam, Derek, additional, Licameli, Greg R., additional, Long, Steve, additional, Lott, David G., additional, Manrique, Dayse, additional, McMurray, James Scott, additional, Meister, Kara D., additional, Messner, Anna H., additional, Mohr, Michael, additional, Mudd, Pamela, additional, Mortelliti, Anthony J., additional, Novakovic, Daniel, additional, Ongkasuwan, Julian, additional, Peer, Shazia, additional, Piersiala, Krysztof, additional, Prager, Jeremy D., additional, Pransky, Seth M., additional, Preciado, Diego, additional, Raynor, Tiffany, additional, Rinkel, Rico N. P. M., additional, Rodriguez, Hugo, additional, Rodríguez, Verónica P., additional, Russell, John, additional, Scatolini, María Laura, additional, Scheffler, Patrick, additional, Smith, David F., additional, Smith, Lee P., additional, Smith, Marshall E., additional, Smith, Richard J. H., additional, Sorom, Abraham, additional, Steinberg, Amalia, additional, Stith, John A., additional, Thompson, Dana, additional, Thompson, Jerome W., additional, Varela, Patricio, additional, White, David R., additional, Wineland, Andre M., additional, Yang, Christina J., additional, Zdanski, Carlton J., additional, and Derkay, Craig S., additional

Published
2021
Full Text
View/download PDF

40. Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Author

Shin, Dong M., primary, Nannapaneni, Sreenivas, additional, Patel, Mihir R., additional, Shi, Qiuying, additional, Liu, Yuan, additional, Chen, Zhengjia, additional, Chen, Amy Y., additional, El-Deiry, Mark W., additional, Beitler, Jonathan J., additional, Steuer, Conor E., additional, Roser, Steven M., additional, Klein, Adam M., additional, Owonikoko, Taofeek K., additional, Ramalingam, Suresh S., additional, Khuri, Fadlo R., additional, Chen, Zhuo G., additional, and Saba, Nabil F., additional

Published
2020
Full Text
View/download PDF

44. Tu1382 IS IT REALLY LARYNGOPHARYNGEAL “REFLUX”? LARYNGEAL SYMPTOMS CORRELATE BETTER WITH DYSPHAGIA AND ARE COMMONLY ASSOCIATED WITH ESOPHAGEAL MOTOR DISORDERS

Author

Bloch, John, primary, Obineme, Chuma, additional, Samo, Salih, additional, Godiers, Marie L., additional, Calderon, Lucie, additional, Dietz-Lindo, Karan A., additional, Shahnavaz, Nikrad, additional, Raja, Shreya, additional, Keilin, Steven, additional, Cai, Qiang, additional, McColloch, Nancy, additional, Hatcher, Jeanne, additional, Tkaczuk, Andrew, additional, Klein, Adam M., additional, Christie, Jennifer A., additional, Srinivasan, Shanthi, additional, and Jain, Anand, additional

Published
2020
Full Text
View/download PDF

45. Tu1376 UPPER ESOPHAGEAL SPHINCTER DYSFUNCTION ON FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY IS ASSOCIATED WITH LARYNGEAL HYPERSENSITIVITY

Author

Calderon, Lucie F., primary, Samo, Salih, additional, Godiers, Marie L., additional, Bloch, John M., additional, Obineme, Chuma, additional, Dietz-Lindo, Karan A., additional, Shahnavaz, Nikrad, additional, Raja, Shreya, additional, Patnana, Srikrishna, additional, Keilin, Steven, additional, Cai, Qiang, additional, McColloch, Nancy, additional, Hatcher, Jeanne, additional, Tkaczuk, Andrew, additional, Klein, Adam M., additional, Christie, Jennifer, additional, Srinivasan, Shanthi, additional, and Jain, Anand, additional

Published
2020
Full Text
View/download PDF

47. Pathology Quiz Case 1

Author

Leu, Grace, Klein, Adam M., Deyrup, Andrea T., and Johns, Michael M., III

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results